Market cap
₹6,431 Cr
Recently Viewed
Clear AllNSE: THYROCARE | BSE: 539871
₹404.35
₹-2.25
(-0.55%)
As on 29-Apr-2026IST
Market cap
₹6,431 Cr
Revenue (TTM)
₹792 Cr
P/E Ratio
46.7
P/B Ratio
9.6
Div. Yield
1.7 %
Quality Score
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
₹138 Cr
ROE
17 %
ROCE
27.2 %
Industry P/E
47.25
EV/EBITDA
24.3
Debt to Equity
0
Book Value
₹42
EPS
₹22.6
Face value
10
Shares outstanding
159,165,315
CFO
₹1,248.99 Cr
EBITDA
₹1,541.28 Cr
Net Profit
₹875.36 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Thyrocare Tech
| -9.3 | 11.9 | -11.8 | 33.0 | 40.0 | 4.0 | -- |
|
BSE Healthcare
| 2.8 | 5.2 | 8.2 | 4.9 | 24.7 | 13.9 | 11.2 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Thyrocare Tech
| 45.0 | 39.8 | 4.0 | -44.1 | 18.1 | 69.2 | 1.9 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 | 62.8 | 32.1 | -6.8 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Thyrocare Tech
|
404.4 | 6,431.1 | 792.3 | 135.5 | 23.5 | 26.4 | 46.7 | 9.6 |
| 149.2 | 85.1 | 49.6 | 5.3 | 11.7 | 13.8 | 16.2 | 2.4 | |
| 1,397.8 | 23,415.8 | 2,662.8 | 533.1 | 22.9 | 24.1 | 44.3 | 9.1 | |
| 665.3 | 26,623.2 | 3,626.9 | 315.0 | 15.0 | 13.3 | 88.5 | 11.5 | |
| 581.0 | 1,881.8 | 766.3 | 80.5 | 15.7 | 8.9 | 23.4 | 2.0 | |
| 249.3 | 336.6 | 166.7 | 7.2 | 3.9 | 3.9 | 35.7 | 1.2 | |
| 478.8 | 9,933.1 | 1,566.5 | 169.5 | 14.8 | 12.7 | 59 | 6.6 | |
| 282.6 | 895.6 | 1,231.3 | 29.1 | -4.7 | 4 | 34.4 | 1.3 | |
| 280.8 | 1,468.9 | 294.1 | 32.4 | 17.4 | 15.1 | 44.1 | 6.2 | |
| 1,114.1 | 10,760.2 | 768.1 | 159.9 | 29.2 | 19.3 | 67.5 | 11.9 |
Best of both worlds: profits and dividends
4 min read•By Danish Khanna
2 min read•By Jugal Harpalani
Two unloved stocks to watch out for
4 min read•By Danish Khanna
Thyrocare Technologies Limited provides diagnostic testing services to patients, laboratories, and hospitals in India. It operates through three segments: Diagnostic Testing Services, Imaging Services, and Others. The company conducts various medical... diagnostic tests and profiles of tests that focuses on early detection and management of disorders and diseases, including thyroid, growth, metabolism, auto-immunity, diabetes, anaemia, cardiovascular, infertility, and various infectious diseases. Its profiles of tests include profiles of tests administered under its Aarogyam brand, which offers patients a suite of wellness and preventive health care tests. The company sells glucometer and glucostrips under the brand name Sugarscan; consumables; and radiopharmaceutical products. Thyrocare Technologies Limited was founded in 1996 and is based in Navi Mumbai, India. Thyrocare Technologies Limited is a subsidiary of Docon Technologies Private Limited. Read more
Incorporated
2000
Chairman
--
Managing Director
Rahul Guha
Group
MNC
Headquarters
Navi Mumbai, Maharashtra
Website
Looking for more details about Thyrocare Technologies Ltd.’s IPO? Explore our IPO Details page.
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
Announcements
View AnnouncementsNo News & Announcements are available.
The share price of Thyrocare Technologies Ltd is ₹404.35 (NSE) and ₹404.05 (BSE) as of 29-Apr-2026 IST. Thyrocare Technologies Ltd has given a return of 40.03% in the last 3 years.
The P/E ratio of Thyrocare Technologies Ltd is 46.73 times as on 29-Apr-2026, a 1 discount to its peers’ median range of 47.25 times.
The P/B ratio of Thyrocare Technologies Ltd is 9.63 times as on 29-Apr-2026, a 20 premium to its peers’ median range of 8.02 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
39.72
|
6.65
|
|
2024
|
44.13
|
6.00
|
|
2023
|
11.48
|
4.29
|
|
2022
|
7.75
|
7.82
|
|
2021
|
42.72
|
11.25
|
The 52-week high and low of Thyrocare Technologies Ltd are Rs 536.67 and Rs 289.33 as of 29-Apr-2026.
Thyrocare Technologies Ltd has a market capitalisation of ₹ 6,431 Cr as on 29-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Thyrocare Technologies Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.